lung mechanics; bronchoprotection; prostaglandins; asthma; Ptges; Ptger2; 15-hydroxyprostaglandin AIRWAYS ARE DYNAMIC STRUCTURES that can change their diameter in response to both endogenous and exogenous stimuli. For instance, airways can dilate when it is necessary to move large volumes of air, such as during exercise, and, conversely, upon exposure to toxic fumes or irritating gases, the airway can constrict to limit the exposure of the lungs (18) . The ability of the airways to reversibly alter their size in response to stimuli has been termed airway responsiveness. An exaggerated bronchoconstrictor response to a provoking stimulus is termed airway hyperresponsiveness and is one of the cardinal characteristics of asthma (23).
Acetylcholine release by the parasympathetic airways stimulates G q -coupled receptors on airway smooth muscle, and this pathway is largely responsible for maintaining airway tone (11) . Although sympathetic innervations play less of a role in normal airway homeostasis, the constrictive actions of acetylcholine can be countered by the actions of epinephrine (adrenaline), which acts on ␤-adrenergic receptors expressed by smooth muscle cells (23). Activation of these G s -coupled receptors relaxes airway smooth muscle, increasing lung ventilation. This response is the basis for the most common treatment of asthma: ␤-agonists. Airway tone and responsiveness can be modulated by other mediators, including prostaglandin E 2 (PGE 2 ). PGE 2 is produced from arachidonic acid (AA) by the sequential actions of a number of enzymes. AA is released from the membrane by phospholipase A 2 . The free AA is available to be metabolized by PTGS1 (Cox1) or PTGS2 (Cox2) to PGH 2 , the common precursor of all prostanoids. PGE 2 is formed when PGH 2 is further metabolized by a PGE synthase (PGES). Multiple enzymes capable of carrying out this response have been identified (1, 14, 25, (33) (34) (35) 38) . However, to date, only one has been shown to contribute to the production of PGE 2 in vivo (38) .
PGE 2 can activate four unique high-affinity seven-transmembrane G-coupled protein receptors commonly referred to as EP 1 -EP 4 and encoded by four unique genes, Ptger1-Ptger4 (9, 20, 22) . These receptors, through coupling to various G proteins, can affect a variety of sometimes opposing intracellular signaling pathways (22) . The EP 2 and EP 4 receptors are coupled to G s , and in all cells examined to date, activation of these receptors leads to an increase in cAMP. In contrast, EP 1 and EP 3 would be expected to contribute to smooth muscle contraction, because both can increase intracellular Ca 2ϩ levels and/or decrease intracellular cAMP.
Exogenously administered PGE 2 has been shown to have a complex and sometimes seemingly opposing effect on airways. In clinical studies, pretreatment with inhalated PGE has been shown to be bronchoprotective against a variety of challenges including allergen-, exercise-, and aspirin-induced bronchoconstriction (10, 21, 26, 28) . However, in some trials after PGE inhalation, patients reported transient cough and retrosternal soreness (26). In addition, a small subset of patients, upon inhalation of PGE, experienced profound bronchoconstriction, sometimes requiring rescue with a ␤-agonist (5). In murine models of airway reactivity, PGE 2 inhalation has been shown to cause a small but significant rise in Penh (37) . This response was dependent on the expression of the EP 1 or EP 1 and EP 3 receptors, depending on the mouse strain studied (37) . At the same time, PGE 2 inhalation has been shown to protect against methacholine-induced increase in lung resistance (R L ) (29, 37) . Furthermore, PGE 2 could relax preconstricted tracheal rings.
These actions were dependent on the expression of the EP 2 receptor (8, 29, 37) .
Studies of human airway smooth muscle cells have indicated that these cells express EP 2 receptors (2, 3). The expression of EP 2 by these cells is consistent with a bronchoprotective role of PGE 2 , raising the possibility that modulation of PGE 2 levels might determine the responsiveness of the airways to provocative stimuli. However, a previous attempt to decrease airway responsiveness with chronic overexpression of G s -coupled ␤ 2 -adrenergic receptor (␤ 2 -AR) produced unexpected results (19) . Mice with elevated ␤ 2 -AR expression displayed an exacerbated response to methacholine, suggesting that an adaptive change had occurred, compensating for the constitutive increase in the activity of this G s -coupled pathway. Mice deficient in ␤-adrenergic receptors surprisingly showed an attenuated response to constricting agents (19) . It was important, therefore, to determine whether such compensatory changes would be observed upon alteration of the activity of other G s -coupled receptors expressed by airways.
To determine the impact of alterations in PGE 2 levels on airway responsiveness, we first examined mice in which the available PGE 2 is reduced or mice that lack EP 2 . We next examined mice in which PGE 2 levels are expected to be increased. The first mouse line lacks 15-hydroxyprostaglandin dehydrogenase (PGDH; Hpgd). Hpgd is expressed at high levels in the lung and metabolizes PGE 2 , its preferred substrate, to 15-keto-PGE 2 . In the second mouse line, PGE 2 levels are increased by expression of a transgenic hSP-C-Ptges in the airway epithelia.
MATERIALS AND METHODS
Experimental animals. All studies were approved by and conducted in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals as well as the Institutional Animal Care and Use Committee guidelines of the University of North Carolina at Chapel Hill. Generation of Ptger2 Ϫ/Ϫ (36), Ptges Ϫ/Ϫ (38), and Hpgd Ϫ/Ϫ (4) mice in this study has been previously reported. The Ptger2 mutation was maintained on a relatively inbred 129 background consisting of a mixture of 129/Ola and 129/SvEv. Hpgd Ϫ/Ϫ mice were originally generated on a mixed background of C57BL/6, DBA/2, and 129/SvEv. For the mixed background experiments, heterozygous siblings were mated to generate wild-type and Hpgd Ϫ/Ϫ mice. Inbred C57BL/6 mice homozygous for the mutant Hpgd allele were generated by repeatedly backcrossing the Hpgd mutation onto the C57BL/6 mouse strain for a minimum of four generations and then intercrossing the resulting N4 B6-Hpgd ϩ/Ϫ mice. Intercrosses of B6 mice heterozygous for the disrupted Hpgd allele produced B6-Hpgd Ϫ/Ϫ and B6-Hpgd ϩ/ϩ animals. Generation of transgenic mouse line. A full-length Ptges1 cDNA was generated by RT-PCR from total RNA isolated from murine lungs. (For a schematic representation of the transgene expression construct, see Fig. 7A .) The human surfactant protein C (hSP-C) promoter has been used extensively to generate lung-specific transgenic animals (12, 16, 39) . This promoter fragment has been shown in mice to direct gene expression to distal epithelial bronchiolar cells (12, 16, 39) . Generation of transgenic mice involved colipofection of the transgene construct along with a selectable marker into murine 129/Ola ES cells. Cells were selected for expression of the marker, and clones were genotyped for transgene integration by Southern blotting, using a fragment of the hSP-C promoter as a probe. Transgene-positive cells were injected into C57BL/6 embryos, which were then implanted into pseudopregnant recipient females. Chimeric animals were then bred with B6D2 mice, and the presence of agouti pups confirmed targeted ES cell transmission. Genomic DNA isolation and subsequent Southern blotting with the SP-C probe confirmed transmission of the transgene in pups. Transgene-positive mice were bred to B6D2 mice to generate wild-type and transgene-positive mice on the mixed background. Transgenic-positive animals were obtained in the expected Mendelian ratios consistent with a single genomic integration, developed normally, and had no overt phenotype. (See Fig. 7B , a Northern blot of tissues from both transgene-positive and wild-type littermates showing a lung-specific increase of the Ptges transcript in transgene-positive animals.) Congenic C57BL/6 mice carrying the hSP-C-Ptges transgene were generated by repeated crossing of transgenic mice with purchased C57BL/6 mice. Wild-type littermates were used as controls in these studies. Wild-type C57BL/6 and B6D2 mice were purchased from Jackson Laboratories.
Measurements of airway resistance in anesthetized mice. Mice were anesthetized with 70 -90 mg/kg pentobarbital sodium, tracheostomized, and mechanically ventilated at a rate of 300 -350 breaths/ min, a tidal volume of 150 l, and a positive end-expiratory pressure (PEEP) of 3-4 cmH 2O with a computer-controlled small animal ventilator (Scireq, Montreal, Canada). Once ventilated, mice were paralyzed with 0.8 mg/kg pancuronium bromide. Using the customdesigned software Flexivent (Scireq), we recorded airway pressure and airflow using a precisely controlled piston during a single inspiration and expiration with an amplitude of 150 l and a period of 1 s (SnapShot). Applying this data to the single-compartment equation of motion (Eq. 1) allows determination of R L and dynamic compliance (CDYN):
where
P(t) is pressure at time t, R is resistance, v(t) is flow at time t, C is compliance, V(t) is volume at time t, and P0 is resting pressure (PEEP).
Five separate measurements of lung parameters were taken before exposure to methacholine. These measurements were used to calculate the baseline R L and CDYN for each mouse. Aerosols of methacholine were delivered via a nebulizer (DeVilbiss) through a side port in the ventilator circuit for 30 s at a rate of 200 breaths/min. After methacholine exposure, R L and CDYN were measured every 10 s for 3 min, and the maximum value of RL and minimum value of CDYN for each dose were determined. For the indomethacin-pretreatment experiments, mice received an intravenous tail vein injection of 10 mg/kg indomethacin (Sigma) at least 4 h before the start of the experiment.
Quantitative real-time RT-PCR. Total RNA was extracted from frozen pulverized tissue using RNAzolB (Teltest, Friendswood, TX) according to the manufacturer's instructions. RNA was purified using Qiaprep RNAeasy columns (Qiagen), and cDNA was generated from 4 g of purified RNA using Multiscribe reverse transcriptase (cDNA archive kit; Applied Biosystems, Foster City, CA). cDNA (2.5 ng) was used in amplification reactions with a SYBR green PCR master mix kit (Applied Biosystems) in accordance with the manufacturer's instructions. All amplification were performed in quadruplicate on a Stratagene Mx300P cycler. Primers and probe set for the following genes were purchased from Assays on Demand (Applied Biosystems): Ptges, ␤-actin, Ptgs1, Ptgs2, Hpgd, Ptger2, and Pde4b. Differences in expression between tissues were determined using the comparative threshold cycle (⌬⌬C T) method as suggested by the manufacturer (Applied Biosystems), normalizing each sample to ␤-actin levels. The expression of the transgene was expressed as the degree of change relative to wild-type littermates.
PGE 2 measurement. Lung tissue was homogenized in PBS/1 mM EDTA with 10 g/ml indomethacin. Samples were applied to Amprep C18 octadecyl columns (Amersham) for extraction. PGE 2 levels were assessed using the Correlate-EIA PGE2 kit (Assay Designs). Samples were run in duplicate and normalized to tissue weight.
Statistical analysis. All data are presented as means Ϯ SE. Statistical significance for single data points was assessed using Student's two-tailed t-test. Multivariate repeated-measures analysis of variance (MANOVA) was performed on all dose-response curves. The JMP IN statistical package was used to perform all statistical analyses (SAS, Cary, NC).
RESULTS
Basal tone and airway reactivity in mice with compromised PGE 2 pathways. We first determined whether either loss of the G s -coupled EP 2 receptor for PGE 2 or diminished capacity to produce PGE 2 due to loss of mPGES1 altered basal airway tone and/or airway reactivity in response to methacholine. To do this, we used a direct measurement of lung function. R L and C DYN in mice were calculated by determining resistance and compliance via the equation of motion (Eq. . Mean baseline C DYN values were as follows: Ptger2 Ϫ/Ϫ , 0.035 Ϯ 0.002 ml/cmH 2 O; and wild type, 0.034 Ϯ 0.002 ml/cmH 2 O. Next, we determined whether loss of EP 2 -mediated PGE 2 signaling in the lungs would alter the airway responsiveness to methacholine (a congenitor of acetylcholine that is metabolized less rapidly by acteylcholinesterases). Mice were exposed to doubling doses of aerosolized methacholine (3-100 mg/ml). Response to methacholine was plotted as the peak R L and minimum C DYN values obtained for each dose as a percentage of the baseline R L and C DYN values. Loss of EP 2 did not alter airway responsiveness as measured by either R L or C DYN (Fig. 1) . These experiments were repeated using a congenic C57BL/6 Ptger2 Ϫ/Ϫ mouse pair, and again no difference in either baseline airway function or response to methacholine could be detected using these methods.
The Ptges Ϫ/Ϫ and wild-type mice on the DBA/1lacJ background, similar to the Ptger2 , 0.030 Ϯ 0.001 ml/cmH 2 O; and wild type, 0.030 Ϯ 0.002 ml/cmH 2 O. Next, we determined whether loss of mPGES1-mediated PGE 2 production in the lungs would alter airway responsiveness to methacholine. Airway reactivity was evaluated as described for the Ptger2 Ϫ/Ϫ cohort. Loss of mPGES1 did not alter airway responsiveness as measured by either R L or C DYN (Fig. 2) . Thus neither loss of the EP 2 receptor nor diminished capacity to produce PGE 2 resulted in compensatory changes that alter the responsiveness of the airways to cholinergic stimulation.
Airway function in mice deficient in 15-PGDH. We next determined whether elevated levels of PGE 2 would alter baseline airway tone and/or diminish the response of the airways to methacholine. To do this, we utilized mice lacking 15-PGDH (Hpgd Ϫ/Ϫ ). The inability of these mice to rapidly metabolize PGE 2 in the perinatal period results in failure of the pups to remodel the ductus arteriosus. However, these animals can be rescued by a single injection of indomethacin in the perinatal period. We determined whether loss of this enzyme would lead to a measurable increase in PGE 2 levels in the adult lung (Fig.  3) . A small but significant increase was observed in levels of PGE 2 in the lungs of Hpgd Ϫ/Ϫ animals. The Hpgd mutation was originally studied on a genetic background composed of alleles from three inbred strains of mice: C57BL/6, 129/SvEv, and DBA/2J. However, congenic C57BL/6 Hpgd Ϫ/Ϫ animals also were generated for these studies. No histological changes were apparent on examination of the lungs of either group of animals. We began these studies using a cohort of Hpgd Ϫ/Ϫ mice (n ϭ 6 and 7, respectively). BL, baseline. 0.001 ml/cmH 2 O. However, these differences were not maintained when baseline parameters were measured in congenic B6-Hpgd Ϫ/Ϫ pairs. We next determined whether Hpgd Ϫ/Ϫ mice have altered airway responsiveness to methacholine, again beginning our studies with mice of mixed genetic background. Hpgd Ϫ/Ϫ mice have a significantly lower reactivity to methacholine compared with wild-type mice as measured by percentage of baseline R L on the mixed background ( Fig. 4 ; P Ͻ 0.05, MANOVA all points; P Ͻ 0.05, t-test for 100 mg/ml dose). There was no difference in percentage of baseline C DYN in response to methacholine between Hpgd Ϫ/Ϫ and wild-type mice at any dose (Fig. 4) . Both the protection from methacholine constriction as measured by percentage of baseline R L and the lack of protection as measured by percentage of baseline C DYN were also observed when the studies were repeated using N4 B6 Hpgd Ϫ/Ϫ and wild-type mice (Fig. 5 ). To verify that the difference in airway reactivity in the Hpgd Ϫ/Ϫ mice was due to altered prostanoid metabolism at the time of challenge, we pretreated a mixed background cohort of Hpgd Ϫ/Ϫ and wild-type mice with indomethacin (a potent Fig. 2 . RL and CDYN measured after exposure of DBA/1lacJ Ptges Ϫ/Ϫ and wild-type mice to methacholine. Response to each methacholine dose was plotted as the mean (ϮSE) peak RL and minimum CDYN values obtained in the 3 min following a 30-s aerosol of methacholine for each group: ■, wild-type controls; ᮀ, Ptges Ϫ/Ϫ mice (n ϭ 11 for both groups). (Fig. 6) .
Fig. 3. Prostaglandin E2 (PGE2) levels in lungs of 15-hydroxyprostaglandin (PGDH)-deficient (Hpgd
Evaluation of airway responsiveness in mice overexpressing mPGES1. Although 15-PGDH has been shown to preferentially metabolize PGE 2 compared with other prostanoids, we cannot rule out the possibility that the protection against methacholine-induced constriction is mediated by change in the levels of other prostanoids, and not solely an increase in PGE 2 levels. To begin to address this, we generated a transgenic mouse line carrying a Ptges transgene under the regulation of a lung-specific SP-C promoter. This human SP-C promoter fragment has been shown in mice to direct gene expression to distal epithelial bronchiolar cells (12, 16, 39) .
A schematic representation of the transgene expression construct is shown in Fig. 7A . Preliminary analysis was carried out with cohorts of transgenic and wild-type mice on the mixed background described in MATERIALS AND METHODS. Animals carrying the transgene were obtained in the expected Mendelian ratios consistent with a single genomic locus integration, developed normally, and had no overt phenotype. Histological examination of the lungs using hematoxylin-eosin or Masson trichrome blue stain reveal no gross abnormality in lung tissue (data not shown). Figure 7B is a Northern blot of tissues from both transgene-positive and wild-type littermates showing lung-specific increase of Ptges transcript in transgene-positive animals. A cohort of N3 B6 hSP-C-Ptges and wild-type animals were assessed for gene expression using real-time PCR. The transgene-positive mice had significantly more Ptges transcript than wild-type littermates as measured relative to wild type with the use of quantitative RT-PCR (Fig. 7C) . Measure- Fig. 6 . RL and CDYN in mixed background Hpgd Ϫ/Ϫ and wild-type mice after exposure to methacholine following indomethacin pretreatment. Mice were given 10 mg/kg indomethacin by tail vein at least 4 h before the experiment. Response to each methacholine dose was plotted as mean (ϮSE) peak RL and minimum CDYN values obtained in the 3 min following a 30-s aerosol of methacholine for each group: ■, wild-type controls; ᮀ, Hpgd Ϫ/Ϫ mice (n ϭ 9 and 10, respectively). ment of PGE 2 in whole lung homogenates showed a trend toward higher levels in the hSP-C-Ptges mice; however, these did not achieve statistical significance (data not shown). To determine whether expression of the transgene resulted in altered expression of genes involved in PGE 2 synthesis or in the actions of PGE 2 after receptor binding, we carried out real-time PCR analysis on RNA prepared from the lungs of four transgenic animals and five nontransgenic littermates. No significant difference in expression of the genes Hpgd, Ptgs1, Ptgs2, Ptger2, Pde4b, or ␤-actin was detected.
Basal tone and airway reactivity in SP-C-Ptges transgenic mice. A cohort of hSP-C-Ptges and wild-type littermates was generated by breeding a chimera generated from 129/SvEv ES cells carrying the transgene with B6D2 purchased mice. Assessment of baseline lung parameters reveals that the transgenic mice did not significantly differ from the wild-type mice in baseline R L or C DYN values. Mean baseline R L values were as follows: hSP-C-Ptges, 1.37 Ϯ 0.05 cmH 2 Generation of a dose-response curve to methacholine as measured by percentage of baseline R L showed that the transgenic mice have a significantly attenuated response to methacholine. However, unlike the Hpgd Ϫ/Ϫ mice, we also noted a significant attenuation in the percentage of baseline C DYN change in these mice (Fig. 8) . These changes in mice of mixed genetic background were recapitulated in studies of the mice in which the transgene had been moved onto a more homogenous genetic background (Fig. 9) .
To verify that the attenuation in responsiveness in the transgenic mice on the mixed background is due to altered prostanoid metabolism at the time of challenge, we pretreated a cohort of transgenic and wild-type mice with indomethacin before measuring their airway reactivity invasively. Mice received 10 mg/kg indomethacin intravenously at least 4 h before the experiment. Assessment of baseline lung parameters reveals that the indomethacin pretreatment did not significantly alter baseline lung parameters in either group (data not shown). Generation of a dose-response curve to methacholine as measured by percentage of baseline R L and C DYN demonstrated no significant difference between the groups when pretreated with indomethacin ( Fig. 10) .
DISCUSSION
Previous studies have shown that PGE 2 can protect against bronchoconstrictive challenges induced in humans (10, 21, 26, 28) . Studies using mice lacking each of the four known PGE 2 receptors showed that these protective actions were mediated in large part by the EP 2 receptor (8, 29, 37) . We have shown in the present study that loss of the EP 2 receptor does not alter the basal tone of the airways and does not alter the response of the mice to methacholine. This is in stark contrast to the observation that loss of ␤-adrenergic receptors leads to decreased responsiveness to methacholine challenge (19) . Similarly, we have found that both baseline tone and response to methacholine were not altered in mice homozygous for a mutation in Ptges. We cannot rule out the possibility that loss of mPGES1 has only a small effect on the capacity of specific cellular compartments within the lung to produce PGE 2 . mPGES1 is one of a number of gene-encoding proteins believed to be capable of converting PGH 2 to prostaglandin. These include mPGES1, mPGES2, GSTM2, GSTM3, and cPGES/p23 (1, 14, 25, (33) (34) (35) 38) . To date, however, mPGES1 is the only enzyme that has been shown to contribute to PGE 2 production in vivo (38) . Because the phenotype of the Ptges Ϫ/Ϫ mice does not recapitulate all of the phenotypes observed in the various PGE 2 receptor-deficient mice, presumably other pathways for the production of PGE 2 exist in vivo. High levels of expression of this synthase are observed in the lung, and it is therefore reasonable to expect that it normally contributes to the production of PGE 2 by this organ, despite the fact that we were unable to measure change in PGE 2 levels in the healthy airway.
We utilized two different approaches to increase PGE 2 levels: mice lacking PGDH and mice expressing a lung- specific mPGES1 transgene. First, we examined mice lacking the enzyme PGDH. This enzyme is expressed at extremely high levels in the lung and has been shown to actively convert PGE 2 into the less active metabolite 15-hydroxy-PGE 2 . Consistent with this, we detected a small but significant increase in PGE 2 levels in the Hpgd Ϫ/Ϫ mice. Initially, the studies of the Hpgd Ϫ/Ϫ mice were carried out on mice of mixed genetic background or on experimental and control littermates generated from N4 B6 Hpgd ϩ/Ϫ animals. In these studies a subtle but significant change in baseline lung mechanics was observed. Interestingly, this difference was not sensitive to indomethacin, suggesting that it was not directly dependent on PGE 2 production at the time of assessment. We propose the possibility that these differences were the result of 129 alleles that continued to cosegregate with the Hpgd mutant allele. This interpretation was supported by our failure to observe these differences in the N7 generation. In contrast, all Hpgd Ϫ/Ϫ mice studied showed an attenuated response to methacholine-induced bronchoconstriction, and this protection was indomethacin sensitive. In these animals it is expected that the relative production of PGE 2 by the various populations of cells will not be altered spatially but, rather, that the survival of the metabolite will be extended. However, PGDH also has been shown to metabolize other eicosanoids with a 15-hydroxyl group (7). It is therefore possible that the protection observed was caused by an increase in levels of some other prostanoid. Alternatively, the protective actions of increased PGE 2 in the Hpgd Ϫ/Ϫ mice might be limited by slight increases in metabolites with bronchoconstrictive actions.
It was therefore important to verify our results using mice that we expected to differ only in PGE 2 levels in the lungs. We therefore generated mice carrying a lung-specific mPGES1 transgene. These mice showed remarkable similarity to the Hpgd-deficient mice. No change in baseline parameters was observed. Transgenic mice were protected against methacholine-induced reactivity, and the change in R L was of a similar magnitude to that observed in the Ptges Ϫ/Ϫ mice. However, further analysis revealed that the hSP-C-Ptges transgenic mouse line additionally shows significant protection from changes in C DYN in response to methacholine. The hSP-C promoter used in generation of this mouse line has been shown by others to direct transgene expression predominately in the distal bronchiolar regions of the adult murine lung (12, 16, 39) . Changes in R L have been postulated to reflect changes in central/proximal airways, whereas changes in C DYN reflect changes in peripheral/distal airways (6, 13, 15, 17, 32) . This protection to changes in C DYN is presumably due to augmented PGE 2 synthesis in the distal regions of the airway.
The protective actions of PGE 2 are mediated in a large part by activation of the EP 2 receptor. It is interesting to speculate that the observation that difference in the impact of increased activity of the EP 2 pathway versus the impact of constitutive increase in the activity of the ␤-adrenergic receptor pathway is related to intrinsic differences in regulation of EP 2 and ␤ 2 -AR signaling. Penn et al. (27) , using smooth muscle culture, have shown that ligand binding to the ␤ 2 -AR leads to rapid desensitization via ␤-arrestin-mediated receptor internalization. In contrast, the desensitization of the EP 2 receptor is limited, perhaps related to the short cytoplasmic tail and lack of sites suitable to phosphorylation by kinases compared with multiple sites in the ␤ 2 -AR and EP 4 proteins (24, 27, 31). It is possible that the continual desensitization of the ␤ 2 -AR leads to induction of intracellular signals that bring about long-term adjustments in cell physiology. Studies in other cell systems have suggested that the binding of ␤-arrestin to phosphorylated G protein-coupled receptors also leads to new signals via the activation of various mitogen-activated protein kinases (30) . The lack of EP 2 receptor phosphorylation stimulated desensitization might prevent these adaptive changes in smooth muscle cells.
Previous studies demonstrated that the protective actions of PGE 2 could be distinguished from the bronchoconstrictive/ irritant action: the protective action was mediated largely by the EP 2 receptor, whereas the EP 1 and EP 3 receptors were shown to be responsible for restricting airflow (8, 29, 37) . These results suggested that EP 2 -specific agonists would provide the beneficial actions of PGE 2 without the complications of bronchoconstriction observed in some patients with PGE 2 inhalation. Our present studies further support the potential of the EP 2 receptor as a target in the treatment of restricted air flow, suggesting that the desensitization and compensatory changes observed with ␤-adrenergic receptor agonist might not occur upon stimulation of this pathway.
